Trial Summary:

Phase III randomised, multicentre international trial to determine the relation between dose and clinical activity of STI-571 in patients with unresectable or metastatic malignant gastrointestinal stromal tumors expressing the c-KIT receptor tyrosine kinase (CD117). Gastrointestinal stromal tumours are rare and highly resistant to standard chemotherapy and radiation. A new chemotherapy tablet, STI-571 (Glivec), has produced dramatic responses in people with this kind of cancer. This trial is comparing higher and lower doses of STI-571. Trials of STI-571 in other cancers are being planned around the world.

Supported By:

Novartis Pharmaceuticals Australia; Novartis International AG (Switzerland); European Organisation for Research and Treatment of Cancer (Belgium); AGITG

Eligibility:

Patients with unresectable or metastatic malignant gastrointestinal stromal tumors

Registration ID:

ACTRN12605000138684

Participation:

International

Australian Lead Group:

AGITG

Status:

Closed

Activation Date:

01/02/2001

Chairs:

John Zalcberg (Australia)

Contact:

eortc62005.study@sydney.edu.au